ada standards of care 2025 glp-1 dpp-4 combination not recommended 2025-ADA-SOC-Slide-Deck-all-recommendations-FINAL-12-9-24.pptx Insulin Versus Established GLP-1 Receptor

Key Takeaways Tesamorelin is FDA-approved: it is the only GHRH analog with an approved indication for visceral fat reduction, giving it one of the best-documented clinical safety profiles among peptides

These medications work by mimicking incretin hormones, which enhance insulin secretion, suppress glucagon release, and significantly reduce appetite through delayed gastric emptying and central nervous system effects

Whenever you do eat, youre likely going to eat a much smaller amount than before, so make sure its packed with long-lasting nutrition

GLP-1R regulation of food intake The reduction in body weight induced by GLP-1R agonists is largely attributed to a reduction in food intake